Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO

4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 18, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news